Schnoll 2016.

Study characteristics
Methods	Study design: secondary analysis of RCT Country: USA Data collection period: June 2009 – April 2014 Registry ID: ClinicalTrials.gov: NCT01047527
Participants	Number of participants: N = 180; Number included in meta‐analysis: N = 180 Sample characteristics (at baseline): Age (mean): 45.9 years (SD 12.3); Sex (% male): 50% (90/180) Population category: general population; Specific population: people who smoked taking part in a RCT of standard (8 weeks), extended (24 weeks), or maintenance (52 weeks) transdermal nicotine therapy Nicotine dependence: FTND: 5.3 (SD 1.9); Baseline cigarettes per day: 16.9 (SD 8.4); Motivation to quit: selected by motivation to quit
Interventions	Behavioural support for smoking cessation: all participants received brief counselling (8 sessions) based on established treatment guidelines and focused on preparing for cessation, managing urges and triggers to smoking, and developing strategies to avoid relapse Pharmacological support for smoking cessation: participants randomised to standard (8 weeks), extended (24 weeks), or maintenance (52 weeks) transdermal nicotine therapy (21 mg); for the current study, only participants randomised to 8 weeks of treatment were included in order to standardise nicotine patch treatment duration Psychotherapeutic or psychoactive support for mental health or mood: did not receive mood management.
Outcomes	Definition of cessation used: point‐prevalence abstinence at 6 months ‐ self‐reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence Measure of biovalidation: expired CO (≤ 10 ppm) Definition of people who continued to smoke used: exact definition not reported; participants who withdrew from the study, failed to provide a CO sample, or had a CO greater than 10 ppm were considered continuing to smoke Time point(s) at which follow‐up was conducted: week 8 and 6 months Outcome category: Anxiety, Depression Outcome measure(s): Beck Anxiety Inventory (BAI); Inventory of Depressive Symptomology (IDS)
Funding source	This research was supported by grants from the National Institute on Drug Abuse (R01DA025078 and R01DA033681) and from the National Cancer Institute (R01CA165001 and P50CA143187)
Author conflicts of interest	Dr.Schnoll and Dr. Hitsman receive medication and placebo free of charge from Pfizer and have provided consultation to Pfizer; Dr.Schnoll has also consulted with GlaxoSmithKline; these companies had no involvement in this study
Notes	Outcome data source: Published data